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during cell development. For example, it is possible that
the Vav1/3 doubly deficient cells have upregulated
expression of other Rac GEFs in an attempt to normal-
ize Rac signaling leading to actin polymerization re-
sponses, which may mask the true involvement of Vav
proteins in FcgR signaling as suggested by cell line
types of experiments (Patel et al., 2002). Similarly, these
studies were all done with CSF-1-stimulated bone-mar-
row-derived macrophages. Obviously, this macrophage
growth factor stimulates a number of intracellular sig-
naling pathways, including tyrosine kinase pathways,
since the CSF-1R is a receptor tyrosine kinase, which
could alter the involvement of Vav proteins in FcgR ver-
sus CR3-mediated phagocytosis when compared to
non-CSF-1-treated cells. It would not be surprising if
phagocytic receptor signaling turned out to be different
in different types of leukocytes such as tissue macro-
phages or blood-derived neutrophils. As such, it may
be just as instructive to look for similarities between
newer studies done with primary cells from knockout
mice and past studies using cell line models. For exam-
ple, Hall et al. found that recruitment of activated Rac1
to the phagocytic vesicle was independent of Vav pro-
teins, as was reported in J774 macrophages (Caron
and Hall, 1998). Recruitment of Rac proteins to the
membrane for localized actin polymerization during
phagocytosis may be more dependent on the newly de-
scribed Ras GAP protein termed CAPRI and not on as-
sociation with GEFs such as the Vav family members
(Zhang et al., 2005). Overall, these exciting new results
modify the ways we think about intracellular signaling
from phagocyte receptors. Understanding these path-
ways, in all the different types of primary phagocytes in-
volved in innate immunity, will be critical if we are to ra-
tionally design therapeutics to target these pathways in
inflammatory and autoimmune disorders.
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Patients with atopic dermatitis (AD) have an increased
risk of infection with several viruses compared to pa-
tients with other inflammatory skin disorders such as
psoriasis. In this issue of Immunity, Howell et al.
(2006) find that the cytokine milieu in the skin of AD
patients profoundly affects the innate response to
vaccinia virus (VV) by blocking production of the anti-
microbial peptide LL-37.
Antimicrobial peptides (AMPs) are an important compo-
nent of the innate immune system in most living organ-
isms. They are of variable length, sequence, and struc-
ture, but most are small, cationic, and amphipathic. All
AMPs exhibit broad spectrum antimicrobial function
against bacteria, fungi, yeast, and enveloped viruses.
Two important subgroups of AMPs in mammals are
cathelicidins and defensins. Cathelicidins are stored in
cells in an unprocessed form, each comprised of a highlyconserved signal sequence, a sequence homologous
to cathelin (a cathepsin L inhibitor), and a more vari-
able C-terminal sequence with antimicrobial action. In
humans, only one cathelicidin has been identified; the
unprocessed form is termed hCAP-18 and the cleaved
antimicrobial peptide LL-37 (Zanetti, 2004). The mecha-
nism of action of most AMPs, including LL-37, is thought
to be 2-fold; first, these peptides have a net positive
charge and thus are capable of binding to microbial
membranes. AMPs also have the ability to fold into am-
phipathic structures and thus can then insert into the
membrane, thus disrupting its integrity. However, more
recently, other roles for AMPs have been proposed that
involve various interactions with host cells (discussed
further later).
hCAP-18 and LL-37 have been shown to be expressed
in neutrophils, lymphocytes, monocytes, NK cells, mast
cells, and a range of epithelial cells including keratino-
cytes and have been detected in various secretions, in-
cluding sweat (Zanetti, 2004). hCAP-18 is upregulated
in the skin in response to infection (Zanetti, 2004) and
also in inflammatory skin disorders such as psoriasis
(Ong et al., 2002). In contrast, atopic dermatitis (AD) is
a common chronic Th2-type inflammatory skin disease
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246Figure 1. Th2 Cytokines Block the Produc-
tion of the Antimicrobial Peptide LL-37
Viral dsRNA binds to TLR3 located in intracel-
lular vesicles, resulting in activation of various
signaling pathways including NF-kB. This
pathway mediates the upregulation of pro-
inflammatory cytokines and, either directly
or via the action of these cytokines, hCAP-
18. Cleavage of hCAP-18 releases the antimi-
crobial peptide LL-37, which has antiviral
properties. The Th2 cytokines IL-4 and IL-13
induce activation of STAT6, which blocks
the NF-kB signaling pathway.that does not show upregulation of hCAP-18, LL-37, and
other AMPs (Ong et al., 2002). Individuals with AD are ex-
cluded from smallpox vaccination due to their propen-
sity to develop eczema vaccinatum, a disseminated viral
skin infection. It is estimated by some that this risk pre-
cludes nearly 50% of the general population from small-
pox vaccination, as nearly 15% of children have AD and
people in close contact with these patients are contrain-
dicated for vaccination (Nomura et al., 2003). In this issue
of Immunity, Howell et al. (2006) show that the interleu-
kin-4 (IL-4) and IL-13 cytokine milieu of AD skin (Nomura
et al., 2003) is able to radically subvert the innate immune
response to vaccinia virus (VV) through the downregula-
tion of LL-37 (Figure 1). The authors have previously
shown that LL-37 exhibits direct antiviral activity against
VV, most probably through disrupting the integrity of the
virus membrane (Howell et al., 2004). Here, Howell et al.
show that exposure of human explants of normal and
psoriatic skin to VV induces substantial expression of
LL-37. In contrast, VV failed to induce LL-37 expression
in AD skin explants. This was reflected in the replication
of VV, which was markedly greater in AD skin than in pso-
riasis and normal skin. Indeed, exogenous application of
LL-37 to AD skin explants at physiological concentra-
tions inhibited VV replication. The importance of catheli-
cidins in the innate resistance to VV was also confirmed
in mice deficient in CRAMP, the murine ortholog of LL-
37, which exhibited higher VV replication in skin than in
control animals.
AD skin shows an overexpression of the Th2 cytokines
IL-4 and IL-13 and a corresponding lack of the Th1 cy-
tokines IL-12 and interferon-g (IFN-g) (Nomura et al.,
2003). The role of IL-4 and IL-13 in LL-37 expression
and VV growth was investigated by adding these cyto-
kines to human keratinocytes—the result was a sub-
stantial reduction in LL-37 amounts and augmentation
of VV replication. Similarly, antibodies to IL-4 and IL-13
reversed the suppressed LL-37 production and en-
hanced VV replication in AD skin. Howell et al. (2006) also
examined the mechanism by which these Th2 cytokines
might be blocking the production of LL-37. Signal trans-
ducers and activators of transcription (STATs) are afamily of transcription factors that provide a link between
cytokine receptors and subsequent gene transcription.
The described IL-4- and IL-13-mediated effects were
STAT6 dependent, as CRAMP expression was not af-
fected by these cytokines in the skin of STAT6-deficient
mice. In addition, Toll-like receptor 3 (TLR3), which
recognizes double-stranded RNA (dsRNA) and thus
plays a role in the host response to viruses (Schro¨der
and Bowie, 2005), mediated production of VV-induced
LL-37. TLR3 signaling involves activation of NF-kB, and
STAT6 is known to inhibit this pathway. However, ex-
actly how NF-kB signaling results in upregulation of
LL-37 is unclear. To this end, the authors examined
the amounts of proinflammatory cytokines produced in
AD skin and found that treatment with anti-IL-4 and/or
IL-13 had no effect on the amounts of the cytokines
IFN-g, IFN-b1, and IFN-a1. Because the CRAMP pro-
moter has been shown to contain an NF-kB site, it is
possible that NF-kB signaling may directly regulate
cathelicidin expression at the transcriptional level (Pes-
tonjamasp et al., 2001). Thus, the mechanism of induc-
tion of LL-37 remains unclear, and further work is re-
quired to determine whether induction of LL-37 occurs
directly via the NF-kB pathway or via secretion of proin-
flammatory cytokines other than those tested in this
manuscript.
Although Howell et al. (2006) clearly demonstrate the
importance of LL-37 in regulating VV replication in skin
biopsies, the question still remains as to how important
this is in the control of disseminated VV infections in pa-
tients with AD after smallpox vaccination. There are an-
imal models of AD available, which could help define
further the role LL-37 plays in the control of VV under
Th2 conditions in vivo.
AMPs can inhibit the replication of other viruses such
as herpes simplex virus-1, adenovirus, and HIV-1
in vitro, although generally at concentrations thought
to be higher than those found in cellular fluids (Stein-
straesser et al., 2005). It will be interesting to know what
other enveloped viruses are sensitive to the action of
LL-37 and whether this AMP plays a role in protecting
against infection.
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pathogenesis have largely focused on the adaptive im-
mune response. For example, insertion of the IL-4 gene
into the genome of poxviruses has also shown the im-
portance of the cytokine milieu in the generation of anti-
viral immunity. IL-4 expression dramatically suppresses
the induction of cytotoxic T cell activity by inhibiting
CD8+ T cell proliferation and greatly augments the
pathogenicity of the recombinant virus, even in previ-
ously immunized animals (Jackson et al., 2001). Howell
et al. (2006) now direct our attention to the role these
Th2 cytokines play in preventing optimum innate im-
mune responses to viruses and raise the question of
whether this may influence the ensuing adaptive re-
sponses. LL-37 has been suggested to have various im-
munoregulatory roles that may direct adaptive immune
responses such as acting as a chemotactic factor for
various inflammatory cells, triggering degranulation of
mast cells, and inducing the differentiation of DCs into
a Th1-inducing phenotype (reviewed in Bowdish et al.
[2005]). While studies on the role of LL-37 in immunoreg-
ulation will require more complex model systems than
the skin biopsies of AD patients, the current study does
beg the question of any further roles for LL-37, possibly
in addition to direct antiviral activity, which the authors
consider to be the main mechanism of action of this
AMP. The availability of CRAMP-deficient mice will
enable such studies to be undertaken. Thus, LL-37
seems to have roles in a cascade of events leading to
the activation of both innate and adaptive immune
responses, and Howell et al. present the possible mech-
anism by which this innate response, at least, can be
subverted in the case of patients with AD. Due to themultiple described activities of AMPs, it will be challeng-
ing to harness the properties of these molecules as ther-
apeutic agents.
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